PHXM Stock Overview
A biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.72 |
| 52 Week High | €5.00 |
| 52 Week Low | €1.50 |
| Beta | 1.82 |
| 11 Month Change | -1.49% |
| 3 Month Change | -1.71% |
| 1 Year Change | -60.23% |
| 33 Year Change | -91.92% |
| 5 Year Change | -95.90% |
| Change since IPO | -98.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHXM | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 3.1% | -6.8% | -1.5% |
| 1Y | -60.2% | -27.4% | -3.5% |
Return vs Industry: PHXM underperformed the French Biotechs industry which returned -26.4% over the past year.
Return vs Market: PHXM underperformed the French Market which returned -3.5% over the past year.
Price Volatility
| PHXM volatility | |
|---|---|
| PHXM Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.1% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: PHXM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: PHXM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 68 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| PHXM fundamental statistics | |
|---|---|
| Market cap | €17.22m |
| Earnings (TTM) | -€21.92m |
| Revenue (TTM) | €2.14m |
8.0x
P/S Ratio-0.8x
P/E RatioIs PHXM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHXM income statement (TTM) | |
|---|---|
| Revenue | €2.14m |
| Cost of Revenue | €0 |
| Gross Profit | €2.14m |
| Other Expenses | €24.06m |
| Earnings | -€21.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,023.91% |
| Debt/Equity Ratio | 51.8% |
How did PHXM perform over the long term?
See historical performance and comparison